Clinical trialNCT05674175RecruitingPhase 1/PHASE2Interventional

Co-administration of CART22-65s and huCART19 for B-ALL

SponsorStephan Grupp MD PhDEnrollment93B Lineage Lymphoblastic LymphomaB-cell Acute Lymphoblastic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Regina Myers, MD
Children's Hospital of Philadelphia
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Autologous, humanized anti-CD19 CAR T cell therapyAutologous, humanized anti-CD22 CAR T cell therapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Jan 2023
Primary completion: 1 Jul 2028
Completion: 1 Jul 2029
Last update posted: 27 Mar 2026
Registered enrollment: 93
Registry id: NCT05674175

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.